Table 5.

The response rate of each regimen for advanced or recurrent cervical cancer

Clinical trial	Regimen	RR (%)	PFS (month)	OS (month)
GOG; Gynecologic Oncology Group; RR, response rate; PFS, progression free survival; OS, overall survival; PTX, paclitaxel; CDDP, cisplatin; GEM, gemcitabine; *, P<0.05; **, P<0.01.
GOG169 (33)	PTX + CDDP	36.0**	4.8**	9.7
	CDDP alone	19.0	2.8	8.8
GOG179 (34)	CDDP alone	13.0	2.9	6.5
	topotecan + CDDP	27.0*	4.6*	9.4*
GOG204 (35)	GEM + CDDP	22.3	–	10.3
	topotecan + CDDP	23.4	–	10.3
	vinorelbine + CDDP	25.9	–	10.0
	PTX + CDDP	29.1	–	12.9